Kaedi Bio
Company Type: Therapeutic development
Main focus: Developing cell therapies to treat solid malignancies
Company stage: Clinical
Diseases: Solid malignancies
Genome-editing tool: CRISPR-Cas9
Funding stage:
Location: Nanjing, Jiangsu, China
Website: www.kaedibio.com
Pipeline: www.kaedibio.com/index.php
Partners:
Kaedi Bio is a clinical-stage biotechnology company focused on expanding cell therapies that are currently approved for various haematological malignancies to treat solid cancers. The company’s focus surrounds advancing CAR-T cell therapy by using their proprietary KD-SmCAR platform, a synthetic biology discovery platform to develop novel CAR’s. Kaedi Bio is investigating the use of CRISPR-Cas9 to engineer the surface of T cells in CAR-T development and improve cell therapy efficacy in solid cancers.